Cost-Utilities Analysis of First LINE Treatments on Advanced STAGE EGFR Positive in NON-SMALL CELL LUNG Cancer Patients in Taiwan.
Author(s)
Jian LS1, Yang MC1, Huang LY2, Gau CS2
1National Taiwan University, Taipei, Taiwan, 2Center for Drug Evaluation, Taipei, Taiwan
Cost-utilities analysis of first line treatments on advanced stage EGFR positive in non-small cell lung cancer patients in Taiwan. OBJECTIVES With the Pharmaceutical industry flourishing developed, cancer patients have more treatment choices to cope with the disease.In Taiwan, we have the National Health Insurance(NHI) which can ensure the insured who have catastrophic illness can be take good care of .But with limited resource, how to increase the QALYs of patients and keep sustainable operation of NHI will be an issue.In this study,we do the cost-utilities analysis for first line treatments Gefitinib、Erlotinib and Afatinib with advanced (III &IV) stage EGFR positive in non-small cell lung cancer(nsclc) patients in Taiwan. To find out which first line target therapy treatment give the patients more quality adjusted life-years (QALYs) and enhance the sustainable for National Health Insurance.. METHODS The resource of data is from National Health Insurance Database and Taiwan's national cancer registry database between 2014 to 2017.We compared the difference of the overall survival (OS) ,progression free survival(PFS) and cost. Propensity score matching (PSM)1:1 was performed. The Wilcoxon rank-sum test, generalized estimating equation (GEE), Cox proportional hazards regression and Kaplan-Meier survival curve were used to compare the difference in the clinical outcomes and medical expenditures (cost).Incremental cost-effectiveness ratio (ICER)and quality adjusted life-years (QALYs) were calculated in the cost-utility analysis. This study also used the one-way sensitivity analysis and non-parametric bootstrap to discuss the distribution of ICER. RESULTS In the cost-utility analysis of the first-line treatment strategy for patients with advanced non-small cell lung cancer with EGFR mutation positive, the ICER and QALYs of Afatinib are the most cost-effective among the three first line target therapy strategies. CONCLUSIONS Afatinib is the most cost-effectiveness compares to the others first line treatments for advanced stage EGFR positive in non-small cell lung cancer patients in Taiwan.
Conference/Value in Health Info
2020-09, ISPOR Asia Pacific 2020, Seoul, South Korea
Value in Health Regional, Volume 22S (September 2020)
Code
PDG4
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Oncology